In the United States, most reported cases of hepatitis B occur in adults as a result of behavioural, lifestyle, or occupational exposures, but a significant number of children also become infected in well defined settings. Although only 1-3% of acute hepatitis B virus (HBV) infections occur in children under 5 years of age, they account for 20-30% of all chronic infections. A new strategy for HBV prevention in the USA includes integration of HBV vaccine into childhood immunisation schedules. Vaccination strategies that target high risk groups have not been effective. To determine the frequency and severity of community acquired chronic hepatitis C, patients with acute non-A, non-B hepatitis identified in four sentinel counties in the United States were followed prospectively. Hepatitis C virus (HCV) infection was found in 106 (82%) of 130 patients. Ninety three per cent of the HCV positive patients had a risk factor for their infection: 59% parenteral, 6% sexual or household, and 28% low socioeconomic level. Chronic hepatitis developed in 62%, independendy of the risk factor for infection. HCV-RNA persisted in most patients, including those with biochemical resolution of their hepatitis. This study suggests that HCV may be a major cause of liver disease and persistent viraemia in the United States.
Abstract
In the United States, most reported cases of hepatitis B occur in adults as a result of behavioural, lifestyle, or occupational exposures, but a significant number of children also become infected in well defined settings. Although only 1-3% of acute hepatitis B virus (HBV) infections occur in children under 5 years of age, they account for 20-30% of all chronic infections. A new strategy for HBV prevention in the USA includes integration of HBV vaccine into childhood immunisation schedules. Vaccination strategies that target high risk groups have not been effective. To determine the frequency and severity of community acquired chronic hepatitis C, patients with acute non-A, non-B hepatitis identified in four sentinel counties in the United States were followed prospectively. Hepatitis C virus (HCV) infection was found in 106 (82%) of 130 patients. Ninety three per cent of the HCV positive patients had a risk factor for their infection: 59% parenteral, 6% sexual or household, and 28% low socioeconomic level. Chronic hepatitis developed in 62%, independendy of the risk factor for infection. HCV-RNA persisted in most patients, including those with biochemical resolution of their hepatitis. This study suggests that HCV may be a major cause of liver disease and persistent viraemia in the United States. Adults in general, and groups such as injecting drug users and sexually transmitted disease (STD) patients in particular, have been extremely difficult to reach for delivery of vaccine. One programme designed to provide HBV vaccine free of charge to susceptible drug users and their sexual partners3 found that, of the drug users screened at a variety of community access sites, 54% had been injecting drugs for at least five years. Of the long term drug users, 95% had evidence of previous HBV infection and, overall, only 24% of drug users who were accessed during the programme were susceptible to HBV infection and candidates for vaccination. Factors associated with susceptibility included young age (less than 25 years old), less than two years of drug use, infrequent drug use (less than once a month), and a negative history of imprisonment. In addition, only 39% of those susceptible received at least two doses of vaccine over a six month period of intensive follow up. In contrast, sexual partners of drug users were less likely to have serological evidence of infection (79% were susceptible) and were more likely to receive at least two doses of vaccine (54%). HBV vaccine programmes have been evaluated recently in two sexually transmitted disease clinic populations.4 Results of prevaccination serological screening showed that 20-30% had prior evidence of HBV infection. Only 14% of the population received two doses of vaccine, and only 4% completed the three dose regimen.
An additional problem with the high risk group vaccination strategy for the prevention of HBV infection is that at least 30% of patients cannot be associated with an identifiable risk factor, which places them out of reach of an immunisation strategy that targets only high risk groups. One of the most significant features of HCV infection is the frequency with which patients develop chronic liver disease, although this has been well studied only in those with transfusion associated disease.9 10 To determine the frequency and severity of community acquired chronic HCV, patients with acute NANB hepatitis identified in 1985-1986 in four sentinel counties in the United States were followed prospectively. " Three markers were used to detect HCV infection in serum: antibody to HCV (anti-HCV) by second generation serological assays;'2 HCV-RNA by polymerase chain reaction;'3 and antibody to HCV antigen (anti-HVCAg) by fluorescent antibody blocking assay.'4 HCV infection was found in 106 (82%) of 130 patients; 72% were positive for anti-HCV and 100/% were positive only for HCV-RNA or anti-HCVAg. Ninety three per cent of the HCV positive patients had a risk factor for their infection; 59% parenteral, 6% sexual or household, and 28%/ low socioeconomic level.
Chronic hepatitis developed in 62% Of the HCV infected patients independent of the risk factor for infection. Chronic hepatitis C was found in 67% of patients with a history of blood transfusion, 60% of injecting drug users, 60% of patients with occupational exposure to blood, 83% of patients with sexual or household exposure, 61% of patients associated with low socioeconomic level, and 43% of patients with no risk factor (p>0 05).
Liver biopsies were performed in 30 patients with chronic hepatitis C. Of these, 10 (33%) had chronic active hepatitis (CAH), one of whom also had cirrhosis, 13 (43%) had chronic persistent hepatitis (CPH), and six (20%) had chronic lobular hepatitis (CLH). One patient had portal fibrosis without other histopathological findings; this patient was positive for HCV-RNA. Repeat biopsies were performed in 10 patients; one patient progressed from CPH to CAH over 32 months, and a second patient went from CLH to CPH over 33 months. All patients with a history of blood transfusion who underwent biopsy had CAH compared with 22% of patients with other risk factors for infection (p<OO1).
HCV-RNA was detected 42-48 months after the onset of illness in 12 of 13 chronic hepatitis C patients tested; in two patients, HCV-RNA positivity was intermittent. Persistent HCV infection also occurred in patients without biochemical evidence of chronic liver inflammation. Testing for HCV-RNA was performed on samples collected 42-48 months after acute onset in 15 patients with persistently normal alanine aminotransferase activity throughout follow up; all were HCV-RNA positive. In four patients, detection of HCV-RNA was intermittent.
Conclusion
This study suggests that HCV may be a major cause of chronic liver disease in the United States. Furthermore, patients with biochemical resolution of their hepatitis may remain positive for HCV-RNA, suggesting that persistent infection in the absence of liver imflammation is similar to, but occurs at a much higher rate, than in persons infected with HBV. Thus, there is an urgent need for the development of preventive and treatment measures for persons in all risk groups. 
